Ultime notizie per CareDx (NASDAQ:CDNA) Azioni

CAREDX INC

CareDx

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

WIIM

CDNA

CareDx shares are trading higher after the company announced authorization for a $50 million stock repurchase program.

News

Buybacks

CareDx Authorizes $50M Repurchase Program

Stephens &amp; Co. analyst Mason Carrico reiterates CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Overweight and maintains $40 price target.

Price Target

Reiteration

Analyst Ratings

Stephens & Co. Reiterates Overweight on CareDx, Maintains $40 Price Target

Throughout the last three months, 4 analysts have evaluated CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CareDx, revealing an average target of $29.0, a high estimate of $40.00, and a low estimate of $25.00. This current average has decreased by 7.2% from the previous average price target of $31.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1746446473_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of CareDx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CareDx. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of CareDx's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into CareDx's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into CareDx's Background</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
<h3>A Deep Dive into CareDx's Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining CareDx's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.54% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: CareDx's net margin excels beyond industry benchmarks, reaching -12.23%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): CareDx's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.73%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CareDx's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.11%, the company showcases efficient use of assets and strong financial health.
Debt Management: CareDx's debt-to-equity ratio is below the industry average at 0.08, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For CareDx's Future

HC Wainwright &amp; Co. analyst Yi Chen reiterates CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Neutral and maintains $25 price target.

HC Wainwright & Co. Reiterates Neutral on CareDx, Maintains $25 Price Target

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) affirms FY2025 sales outlook from $365.00 million-$375.00 million to $365.00 million-$375.00 million vs $370.70 million estimate.

Guidance

CareDx Affirms FY2025 Sales Guidance of $365.00M-$375.00M vs $370.70M Est

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.06 by 50 percent. This is a 400 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $84.69 million which beat the analyst consensus estimate of $84.38 million by 0.36 percent. This is a 17.54 percent increase over sales of $72.05 million the same period last year.

Earnings

Earnings Beats

CareDx Q1 Adj. EPS $0.09 Beats $0.06 Estimate, Sales $84.69M Beat $84.38M Estimate

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

Findings from ALAMO Study Show AlloSure Lung is Associated with Prognosis of Chronic Lung Allograft Dysfunction and Restrictive Allograft Syndrome
AlloSure Lung Surveillance Monitoring Identifies the Onset of Acute Cellular Rejection and Treatment Response
CareDx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) – The Transplant Company&#x2122; – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx, together with study collaborators, presented new scientific evidence on the use of AlloSure&#xAE; Lung in clinical practice at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting &amp; Scientific Sessions, held from April 27-30 in Boston, Massachusetts.

Caredx Presents New Scientific Evidence On Use Of Allosure Lung In Clinical Practice At ISHLT 45Th Annual Meeting & Scientific Sessions

Breadth of Data Demonstrates Growing Real-World Adoption and Clinical Importance of CareDx Testing Solutions in Heart and Lung Transplant Patient Management
New SHORE Study Findings Demonstrate that HeartCare is Prognostic of Long-Term Outcomes and Informs Treatment Decisions

Biotech

Events

General

CareDx Presents 60 Abstracts At 2025 International Society For Heart And Lung Transplantation Meeting

Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and lowers the price target from $34 to $26.

Goldman Sachs Maintains Buy on CareDx, Lowers Price Target to $26

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Monday.
Shares of Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) fell sharply in today's pre-market trading <a href="https://www.benzinga.com/quote/HOOD">amid decline in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) prices</a>.
Bitcoin prices fell below the $82,000 mark this morning.
Robinhood shares dipped 6% to $39.40 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) shares dipped 37.7% to $7.00 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) declined 19.9% to $9.21 in pre-market trading. The company, last week, reported fourth-quarter financial results and beat its EPS and revenue estimates.</li>
<li>Marblegate Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GATE#NASDAQ">GATE</a>) shares tumbled 19% to $32.40 in pre-market trading.</li>
<li>Arhaus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) fell 18.3% to $7.00 in pre-market trading after tumbling over 8% on Friday.</li>
<li>NeOnc Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares declined 17.7% to $14.00 in pre-market trading.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) shares dipped 16.7% to $2.50 in pre-market trading.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) declined 14.3% to $15.40 in today's pre-market trading.</li>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) shares fell 11.7% to $1.29 in pre-market trading. KULR Technology Group, on Thursday, announced fourth-quarter earnings, surpassing revenue expectations.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) declined 9.2% to $7.40 in pre-market trading.</li>
<li>Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) shares fell 8.1% to $14.40 in pre-market trading after gaining 7% on Friday.</li>
<li>Innovative Industrial Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) fell 5.7% to $58.30 in pre-market trading. Innovative Industrial Properties reported defaults by Tenants.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44554966/pvh-progress-software-and-3-stocks-to-watch-heading-into-monday">PVH, Progress Software And 3 Stocks To Watch Heading Into Monday</a></li>
</ul>
Photo: Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

$BTC

ARHS

BASE

CAPR

GATE

HOOD

IIPR

INNV

KULR

NTHI

RGTI

Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Shares of Xos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) rose sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/XOS">reported 2024 results</a>.
The company reported its 2024 revenue surged to $56 million, compared to $44.5 million in 2023. The company delivered 297 units in 2024, up from 283 units in the previous year. Its GAAP gross margins improved from a negative 2.9% in 2023 to a positive 7.1% in 2024.
Xos shares jumped 9% to $3.75 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) gained 75.3% to $0.1402 in pre-market trading after falling over 22% on Friday.</li>
<li>Citius Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) rose 50.4% to $1.00 in pre-market trading.</li>
<li>Color Star Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) rose 50% to $1.20 in pre-market trading after falling around 5% on Friday.</li>
<li>iCoreConnect Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCT#NASDAQ">ICCT</a>) gained 37.2% to $0.3910 in pre-market trading after dipping more than 17% on Friday.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) gained 30.1% to $4.45 in pre-market trading after gaining around 12% on Friday. QuantaSing Group, last week, expanded into pop toys market with strategic acquisition of Letsvan.</li>
<li>Know Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNW#NYSE">KNW</a>) rose 19.2% to $0.8701 in pre-market trading after declining 5% on Friday.</li>
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) surged 15.5% to $0.1397 in pre-market trading. AIM ImmunoTech, last week, posted upbeat FY 2024 results.</li>
<li>China Yuchai International Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYD#NYSE">CYD</a>) gained 7.7% to $17.96 in pre-market after declining 8% on Friday.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) gained 6.3% to $20.99 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares fell 48.3% to $0.0176 in pre-market trading after dipping 23% on Friday.</li>
<li>Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) fell 37.7% to $7.00 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) fell 19.9% to $9.21 in pre-market trading. The company, last week, reported fourth-quarter financial results and beat its EPS and revenue estimates.</li>
<li>Hillman Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) declined 19.5% to $7.00 in pre-market trading.</li>
<li>Enzo Biochem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) fell 18.7% to $0.35 in pre-market trading. Enzo Biochem announced plans to voluntarily delist its common stock from the new York Stock Exchange.</li>
<li>Arhaus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) dipped 18.3% to $7.00 in pre-market trading after tumbling over 8% on Friday.</li>
<li>NeOnc Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares dipped 17.7% to $14.00 in pre-market trading.</li>
<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) shares tumbled 15.3% to $0.0288 in pre-market trading after falling over 20% on Friday.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) fell 14.3% to $15.40 in today's pre-market trading.</li>
<li>Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) shares fell 8.1% to $14.40 in pre-market trading after gaining 7% on Friday.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/03/44534977/jim-cramer-healthpeak-properties-is-a-reasonable-reit-recommends-buying-this-health-care-stock">Jim Cramer: Healthpeak Properties Is A &#8216;Reasonable&#8217; REIT, Recommends Buying This Health Care Stock</a></li>
</ul>

CTOR

DGLY

HLMN

ICCT

TILE

Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

On Friday, Mar. 14, 2025, the&nbsp;Cathie Wood-led&nbsp;Ark Invest&nbsp;made significant trades involving&nbsp;GitLab Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>),&nbsp;Intellia Therapeutics Inc&nbsp;(NGM: NTLA),&nbsp;Prime Medicine Inc&nbsp;(NGM: PRME),&nbsp;UiPath Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>),&nbsp;Ibotta Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>),&nbsp;Roblox Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>),&nbsp;Repare Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>), and&nbsp;CareDx Inc&nbsp;(NGM: CDNA).
The PATH Trade:&nbsp;Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) funds sold shares of UiPath Inc. The ARKK fund sold 1,092,269 shares, while the ARKW fund sold 158,650 shares.
With the stock closing at $10.88, the total value of the sold shares was approximately $13.61 million.
The RBLX Trade:&nbsp;Ark Invest&#8217;s ARK Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>) and ARKW funds sold shares of Roblox Corp. The ARKF fund sold 10,057 shares, while the ARKW fund sold 28,700 shares.
With the stock closing at $56.51, the total value of the sold shares was approximately $2.19 million.
The GTLB Trade:&nbsp;Ark Invest&#8217;s ARKK fund bought 81,543 shares of GitLab Inc, with the stock closing at $52.08. This translated to an investment of approximately $4.24 million.
The ARKW fund also purchased 22,610 shares of GitLab Inc, amounting to an investment of around $1.18 million.
The NTLA Trade:&nbsp;The ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARKK funds of Ark Invest bought shares of Intellia Therapeutics Inc. The ARKG fund acquired 11,276 shares, while the ARKK fund purchased 56,244 shares.
With the stock closing at $9.14, the total investment was approximately $0.62 million.
The PRME Trade:&nbsp;Ark Invest&#8217;s ARKK fund sold 46,026 shares of Prime Medicine Inc. The stock closed at $1.79, making the total value of the sold shares around $82,386.
The IBTA Trade:&nbsp;Ark Invest&#8217;s ARKF and ARKW funds bought shares of Ibotta Inc. The ARKF fund acquired 10,967 shares, while the ARKW fund purchased 68,234 shares.
With the stock closing at $37.87, the total investment was approximately $2.99 million.
The RPTX Trade:&nbsp;Ark Invest&#8217;s ARKG fund sold 53,449 shares of Repare Therapeutics Inc.
The stock closed at $1.1, making the total value of the sold shares around $58,794.
The CDNA Trade:&nbsp;Ark Invest&#8217;s ARKG fund sold 47,153 shares of CareDx Inc. The stock closed at $18.9, making the total value of the sold shares around $891,191.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44345022/ray-dalio-has-a-chilling-warning-for-president-trump-debt-crisis-is-imminent-and-an-issue-of-paramount-importance">Ray Dalio Has A Chilling Warning For President Trump: Debt Crisis Is Imminent, And An Issue Of &#8216;Paramount Importance&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

ETFs

ARKF

ARKG

ARKK

ARKW

GTLB

IBTA

NTLA

PATH

PRME

RBLX

RPTX

Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta

Health Care

CareDx's AlloSure Kidney Is Now Validated And Commercially Available For Simultaneous Pancreas-Kidney Transplant Patients

CareDx's AlloSure Heart Is Now Validated And Commercially Available For Pediatric Heart Transplant Patients Under 15

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for CareDx, presenting an average target of $28.75, a high estimate of $40.00, and a low estimate of $24.00. Observing a downward trend, the current average is 4.17% lower than the prior average price target of $30.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741006873_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of CareDx's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for CareDx's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into CareDx's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About CareDx</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>Breaking Down CareDx's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: CareDx displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 4.46%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 101.29%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 26.91%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): CareDx's ROA excels beyond industry benchmarks, reaching 18.12%. This signifies efficient management of assets and strong financial health.
Debt Management: CareDx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where CareDx Stands With Analysts

HC Wainwright &amp; Co. analyst Yi Chen maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Neutral and lowers the price target from $26 to $25.

HC Wainwright & Co. Maintains Neutral on CareDx, Lowers Price Target to $25

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Barclays BCS: This major global banking and financial services company with more than 325 years of expertise in banking, and operating through an international network in nearly 40 countries and regions in Europe, the U.S., Africa and Asia, the company provides a wide range of financial services to individuals, corporations and institutions, has seen the Zacks Consensus Estimate for its current year earnings increasing 29% over the last 60 days.
<div class="chart_embed">
<h3>Barclays PLC Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/BCS/price-consensus-chart?icid=chart-BCS-price-consensus-chart"><img alt="Barclays PLC Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/a2/1740650708.png" style="height:283px; width:610px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/BCS/price-consensus-chart?icid=chart-BCS-price-consensus-chart">Barclays PLC price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/BCS?icid=chart-BCS-price-consensus-chart">Barclays PLC Quote</a>
</div>
CareDx CDNA: This commercial stage company which develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients, has seen the Zacks Consensus Estimate for its current year earnings increasing 9.3% over the last 60 days.
<div class="chart_embed">
<h3>CareDx, Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/CDNA/price-consensus-chart?icid=chart-CDNA-price-consensus-chart"><img alt="CareDx, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/a2/1740650708.png" style="height:282px; width:610px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/CDNA/price-consensus-chart?icid=chart-CDNA-price-consensus-chart">CareDx, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/CDNA?icid=chart-CDNA-price-consensus-chart">CareDx, Inc. Quote</a>
</div>
The Progressive PGR: This company which is one of the major auto insurers in the country, has seen the Zacks Consensus Estimate for its current year earnings increasing 5.8% over the last 60 day.
<div class="chart_embed">
<h3>The Progressive Corporation Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/PGR/price-consensus-chart?icid=chart-PGR-price-consensus-chart"><img alt="The Progressive Corporation Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/df/1740650710.png" style="height:278px; width:610px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/PGR/price-consensus-chart?icid=chart-PGR-price-consensus-chart">The Progressive Corporation price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/PGR?icid=chart-PGR-price-consensus-chart">The Progressive Corporation Quote</a>
</div>
EZCORP EZPW: This company which is engaged in establishing, acquiring, and operating pawnshops which function as convenient sources of consumer credit and as value-oriented specialty retailers of primarily previously owned merchandise, has seen the Zacks Consensus Estimate for its current year earnings increasing 3.2% over the last 60 days.
<div class="chart_embed">
<h3>EZCORP, Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/EZPW/price-consensus-chart?icid=chart-EZPW-price-consensus-chart"><img alt="EZCORP, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/b7/1740650711.png" style="height:283px; width:610px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/EZPW/price-consensus-chart?icid=chart-EZPW-price-consensus-chart">EZCORP, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/EZPW?icid=chart-EZPW-price-consensus-chart">EZCORP, Inc. Quote</a>
</div>
EverQuote EVER: This company which operates an online marketplace for consumers shopping for auto, home and renters and life insurance, has seen the Zacks Consensus Estimate for its current year earnings increasing 1.3% over the last 60 days.
<div class="chart_embed">
<h3>EverQuote, Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/EVER/price-consensus-chart?icid=chart-EVER-price-consensus-chart"><img alt="EverQuote, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/ce/1740650716.png" style="height:282px; width:610px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/EVER/price-consensus-chart?icid=chart-EVER-price-consensus-chart">EverQuote, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/EVER?icid=chart-EVER-price-consensus-chart">EverQuote, Inc. Quote</a>
</div>
&nbsp;
You can see&nbsp;<a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">the complete list of today&#39;s Zacks #1 Rank (Strong Buy) stocks here</a>.
&nbsp;
<h2>5 Stocks Set to Double</h2>
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
<a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1726&amp;adid=SYND_BENZ_ZU_5S2DREPORT_ZACKS1RANKADDITIONS_02272025_2420915&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915" style="font-weight:bold">Today, See These 5 Potential Home Runs &gt;&gt;</a>
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ZACKS1RANKADDITIONS_2420915&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=BCS&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_2420915_BCS&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915">Barclays PLC (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/bcs#NYSE">BCS</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=PGR&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_2420915_PGR&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915">The Progressive Corporation (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/pgr#NYSE">PGR</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=EZPW&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_2420915_EZPW&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915">EZCORP, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/ezpw#NASDAQ">EZPW</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=EVER&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_2420915_EVER&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915">EverQuote, Inc. (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/ever#NYSE">EVER</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=CDNA&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_2420915_CDNA&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915">CareDx, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/cdna#NASDAQ">CDNA</a>): Free Stock Analysis Report
<a href="https://www.zacks.com/commentary/2420915/new-strong-buy-stocks-for-february-27th?cid=CS-BENZ-FT-zacks_1_rank_additions-2420915">This article originally published on Zacks Investment Research (zacks.com).</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Fintech news covering the emerging Financial Technology services sector

Fintech

Tech

EVER

EZPW

New Strong Buy Stocks For February 27th

Legal

Press Releases

SHAREHOLDER ALERT: Kaskela Law LLC Announces Class Action Lawsuit Against CareDx, Inc (CDNA) and Encourages Long-Term CareDx Investors to Contact the Firm

CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

CareDx to Report First Quarter 2025 Financial Results

CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting

CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting

CareDx Reports First Quarter 2025 Results

Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders

Comments

CareDx

Notizie

Ultime notizie per CareDx (NASDAQ:CDNA) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO